Amarin vs Maravai LifeSciences
AMRN and MRVI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRN and MRVI compare
Amarin is the larger company, worth 2.6 times as much as Maravai LifeSciences ($5.0B against $1.9B).
Maravai LifeSciences grew revenue faster over the last twelve months (−5.0% versus −22.3% for Amarin).
Amarin keeps more of each dollar of sales as profit, with a net margin of −10.9% compared with −37.1% at Maravai LifeSciences.
Amarin scores higher on the StockData Score (10 against 7 for Maravai LifeSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRN | MRVI |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | $1.9B |
| Share price | $11.31 | $7.40 |
| Change, 1 year | −30.5% | 128% |
| Change, 5 years | −84.5% | −82.2% |
| Beta (5Y) | 0.73 | 0.29 |
| Employees | 80 | 435 |
| StockData Score | ||
| Total score | 10 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 28.4× | 9.2× (better) |
| P/B | 11.3× | 9.4× (better) |
| FCF yield | – | −1.9% |
| Fair value | $7.00 | $2.74 |
| Margin of safety | −61.5% (better) | −170% |
| Growth | ||
| Revenue growth (TTM) | −22.3% | −5.0% (better) |
| Revenue growth, 5Y average | −19.0% | −8.1% (better) |
| Profitability | ||
| Gross margin | 40.9% (better) | 34.9% |
| Operating margin | −18.2% (better) | −56.1% |
| Net margin | −10.9% (better) | −37.1% |
| FCF margin | – | −17.2% |
| Return on equity | −4.2% (better) | −32.9% |
| Return on invested capital | −17.3% (better) | −32.4% |
| Financial health | ||
| Debt / equity | 0.00 | 0.72 (better) |
| Interest coverage | – | −4.9× |
| Current ratio | 3.50 | 4.05 (better) |
| Altman Z-score | 12.95 (better) | 4.57 |
| Piotroski F-score | 7 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 1.0% | 55.5% |
| Held by insiders | 7.0% | 3.6% |
| Insider net buying, 12 months | – | $115K |
| Short interest, % of float | – | 5.6% |
Go deeper
- AMRN stock overview
- AMRN income statement
- AMRN valuation and score
- MRVI stock overview
- MRVI income statement
- MRVI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.